<DOC>
	<DOCNO>NCT00003400</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness high dose chemotherapy plus peripheral stem cell transplantation follow combination chemotherapy treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate complete partial remission rate event free overall survival patient metastatic hormone refractory prostate cancer treat high dose chemotherapy plus peripheral stem cell transplantation follow consolidation chemotherapy . II . Evaluate toxic effect associate treatment patient . III . Evaluate quality life , need analgesic , patient . OUTLINE : Patients stratify stage disease extent metastatic disease . Patients receive daily filgrastim ( G-CSF ) subcutaneously 4 day peripheral blood stem cell collect . Patients receive carmustine IV 2 hour day -2 melphalan IV 20 minute day -1 . Stem cell infusion day 0 . At 3 , 6 , 9 , 12 month transplant , patient receive vinorelbine IV 10 minute cisplatin IV 24 hour . Quality life pain assessed transplantation , discharge transplantation , prior consolidation course , 3 , 6 , 12 month final course chemotherapy . Patients follow least every 3 month first 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 18-45 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic hormone refractory adenocarcinoma prostate progressive hormone base therapy , demonstrate : New metastatic lesion Consecutive series increase PSA level follow hormonal therapy No CNS disease PATIENT CHARACTERISTICS : Age : 18 70 Performance status : SWOG 02 ( unless due bone pain ) Life expectancy : Not specify Hematopoietic : CD34+ least 4 million/kg Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal No active chronic hepatitis liver cirrhosis Renal : Creatinine great 3 mg/dL Cardiovascular : Left ventricular ejection fraction least 50 % Pulmonary : FVC , FEV1 , correct DLCO least 50 % predict ( high resolution CT scan chest P02 least 70 unable complete PFTs ) Other : No active infection require intravenous antibiotic Not HIV positive PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No one course cytotoxic chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>